Autolus Therapeutics plc ADR
Autolus Therapeutics plc ADR (AUTL) Historical Volatility
AUTL 30-day historical volatility is 58%. This ranks in the 2th percentile of readings over the past year.
Read more
Tracking AUTL historical volatility helps you see how much Autolus Therapeutics plc ADR's stock price has actually moved over past periods, giving you a baseline to judge whether current option premiums are fair, cheap, or expensive. While implied volatility tells you what the market expects, Autolus Therapeutics plc ADR's HV tells you what really happened. Use our scanner to monitor AUTL 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of an underlying's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. The AUTL 30 day historical volatility is one of the most widely watched readings because it balances responsiveness with stability. Comparing Autolus Therapeutics plc ADR's HV to its implied volatility reveals the volatility risk premium — when IV sits well above HV, option sellers tend to have an edge; when HV runs hot relative to IV, buyers may be underpaying for movement.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Sizing a long premium trade, modeling a covered call, or hunting volatility arbitrage all come back to one question: how much has the stock actually moved? Our scanner puts Autolus Therapeutics plc ADR's historical volatility side-by-side with implied readings across every lookback window, so you can see exactly where AUTL HV is running hot, cold, or in line. Make the AUTL 30 day historical volatility — and every other window — work for your edge instead of against it.
As of September 25, 2026
As of September 25, 2026
See how volatility has moved over time
Track AUTL historical volatility, spot where IV and realized volatility diverge, and find options that are priced in your favor right now.
Start your 14-day free trial→